Differential sensitivity to interferon influences the replication and transcription of Urabe AM9 mumps virus variants in nerve cells

Microbes and Infection

Volumn 9, Issue 7, 2007, Pages 864-872

  Rosas Murrieta, Nora ^a,b   Herrera Camacho, Irma ^b   Vallejo Ruiz, Verónica ^a   Millán Pérez Peña, Lourdes ^b   Cruz, Carlos ^c   Tapia Ramírez, José ^c   Santos López, Gerardo ^a   Reyes Leyva, Julio ^a  

^a Hospital General de Zona IMSS   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Interferon inhibition; Mumps vaccine; Neurovirulence; Transcription; Urabe AM9

Indexed keywords

CELL PROTEIN; INTERFERON; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN P48; STAT2 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN V;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; MUMPS VIRUS; NERVE CELL CULTURE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

MUMPS VIRUS; RUBULAVIRUS;

EID: 34250380382     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2007.03.005     Document Type: Article

References (28)

1. Carbone K.M., and Wolinsky J.S. Mumps virus. In: Knipe D., and Howley P. (Eds). Fields Virology, Lippincott (2001), Williams and Wilkins, Philadelphia 1381-1400
2. Galazka S.A.M., Robertson S.E., and Kraigher A. Mumps and mumps vaccine: a global review. Bull. WHO 77 (1999) 3-14
3. Dourado J., Cunha S., Teixeira M.G., Farrington C.P., Melo A., Lucena R., and Barreto M.L. Outbreak of aseptic meningitis associated with mass vaccination with a Urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am. J. Epidemiol. 151 (2000) 524-530
4. Dobson R. Mumps cases on the rise in England and Wales. BMJ 330 (2005) 324
5. Brown E.G., Dimock K., and Wright K.E. The Urabe AM9 mumps vaccine is a mixture of viruses differing at amino acid 335 of the hemagglutinin-neuraminidase gene with one form associated with disease. J. Infect. Dis. 174 (1996) 619-622
6. Cusi M.G., Santini L., Bianchi S., Valassina M., and Valensin P.E. Nucleotide sequence at position 1081 of the hemagglutinin-neuraminidase gene in wild-type strains of mumps virus is the most relevant marker of virulence. J. Clin. Microbiol. 36 (1998) 3743-3744
7. Santos-López G., Cruz C., Pazos N., Vallejo V., Reyes-Leyva J., and Tapia-Ramirez J. Two clones obtained from Urabe AM9 mumps virus vaccine differ in their replicative efficiency in neuroblastoma cells. Microbes Infect. 332 (2006) 332-339
8. Reyes-Leyva J., Baños R., Borraz-Argüello M., Santos-Lopez G., Rosas N., Alvarado G., Herrera I., Vallejo V., and Tapia-Ramirez J. Amino acid change 335 E to K affects the sialic-acid-binding and neuraminidase activities of Urabe AM9 mumps virus hemagglutinin-neuraminidase glycoprotein. Microb. Infect. 9 (2007) 234-240
9. Amexis G., Fineschi N., and Chumakov K. Correlation of genetic variability with safety of mumps vaccine Urabe AM9 strain. Virology 287 (2001) 234-241
10. Rubin S.A., Amexis G., Pletnikov M., Li Z., Vanderzanden J., Mauldin J., Sauder C., Malik T., Chumakov K., and Carbone K.M. Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J. Virol. 77 (2003) 11616-11624
11. Sauder C.J., Vandenburgh K.M., Iskow R.C., Malik T., Carbone K.M., and Rubin S.A. Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity. Virology 350 (2006) 48-57
12. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signaling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
13. Fujii N., Yokosawa N., and Shirakawa S. Suppression of interferon response gene expression in cells persistently infected with mumps virus, and restoration from its suppression by treatment with ribavirin. Virus Res. 65 (1999) 175-185
14. Gotoh B., Komatsu T., Takeuchi K., and Yokoo J. Paramyxovirus strategies for evading the interferon response. Rev. Med. Virol. 2 (2002) 337-357
15. Kubota T., Yokosawa N., Yokota S., and Fujii N. C-terminal cys-rich region of mumps virus structural V protein correlates with block of interferon alpha and gamma signal transduction pathway through decrease STAT1-alpha. Biochem Biophys Res Commun. 283 (2001) 255-259
16. Kubota T., Yokosawa N., Yokota S., Fujii N., Tashiro M., and Kato A. Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J. Virol. 79 (2005) 4451-4459
17. Marie L., Durbin J.E., and Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17 (1998) 6660-6669
18. Nishio M., Garcin D., Simonet V., and Kolakofsky D. The carboxyl segment of the mumps virus V protein associates with STAT proteins in vitro via a tryptophan-rich motif. Virology 300 (2002) 92-99
19. Yokosawa N., Yokota S., Kubota T., and Fujii N. C-terminal region of STAT-1a is not necessary for its ubiquitination and degradation caused by mumps virus v protein. J. Virol. 76 (2002) 12683-12690
20. Wang J., Schreiber R.D., and Campbell I.L. STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-α in the central nervous system. Proc. Natl. Acad. Sci. 99 (2002) 16209-16214
21. Wang J., and Campbell I.L. Innate STAT1-Dependent genomic response of neurons to the antiviral cytokine alpha interferon. J. Virol. 79 (2005) 8295-8302
22. Andrejeva J., Childs K.S., Young D.F., Carlos T.S., Stock N., Goodbourn S., and Randall R.E. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. PNAS 101 (2004) 4917264-4917269
23. Staeheli P. Interferon-induced proteins and the antiviral state. Adv. Virus Res. 38 (1990) 147-200
24. Mosca J.D., and Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol. Cell. Biol. 6 (1986) 2279-2283
25. Wright K.E., Dimock K., and Brown E.G. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Virus Res. 67 (2000) 49-57
26. Horvath C.M. Weapons of STAT destruction. Eur. J. Biochem. 271 (2004) 4621-4628
27. Kato A., Kiyotani K., Sakai Y., Yoshida T., Shioda T., and Nagai Y. Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J. Virol. 71 (1997) 7266-7272
28. Huang C., Kiyotani K., Fujii Y., Fukuhara N., Kato A., Nagai Y., Yoshida T., and Sakaguchi T. Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis. J. Virol. 74 (2000) 7834-7841